As of May 2, 2024, the Pacira BioSciences stock's PE ratio is 30.02. This results from the current EPS of $0.91 and stock price of $27.32.
The PE ratio of Pacira BioSciences has averaged 239.81 over the last nine years. The current PE ratio of 30.02 is 87% below the historical average. Over the past nine years, PCRX's PE ratio was at its highest in the Dec 2015 quarter at 1,535.8, when the stock price was $76.79 and the EPS was $0.05. The lowest value was in the Jun 2021 quarter, when it reached 15.09 with a price of $60.68 and an EPS of $4.02.
Maximum annual increase: 260.91% in 2021
Maximum annual decrease: -66.39% in 2023
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 37.08 | -66.39% |
| 2022 | 110.31 | 74.16% |
| 2021 | 63.34 | 260.91% |
| 2020 | 17.55 | N/A |
| 2019 | N/A | N/A |
| 2018 | N/A | N/A |
| 2017 | N/A | N/A |
| 2016 | N/A | N/A |
| 2015 | 1,535.8 | N/A |
| 2014 | N/A | N/A |
PCRX's current P/E ratio is below the 3, 5 and 10-year averages.
| Stock name | PE ratio | Market cap |
|---|---|---|
| PCRX Pacira BioSciences Inc | 29.92 | $1.27B |
| DRRX Durect Corp | N/A | $36.62M |
| HRTX Heron Therapeutics Inc | N/A | $391.61M |
| CPIX Cumberland Pharmaceuticals Inc | N/A | $22.26M |
| CARA Cara Therapeutics Inc | N/A | $42.63M |
| OMER Omeros Corp | N/A | $216.42M |
The price to earnings ratio for PCRX stock is 30.02 as of May 2, 2024.
The 3-year average PE ratio for PCRX stock is 84.36.
The 5-year average PE ratio for PCRX stock is 130.06.
The highest quarterly PE ratio in the last nine years has been 1,535.8 and it was in the Dec 2015 quarter.
PCRX's price to earnings ratio is currently 87% below its 9-year historical average.
The PE ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (May 2, 2024), Pacira BioSciences's stock price is $27.32. The earnings per share for the trailing twelve months (TTM) ending Dec 2023 is $0.91. Therefore, Pacira BioSciences's P/E ratio for today is 30.02. PE RATIO(30.02) = STOCK PRICE($27.32) / TTM EPS($0.91)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.